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ABSTRACT 
Crohn’s disease (CD) is an idiopathic inflammatory bowel disease (IBD) 
characterized by and inappropriate inflammatory response. Biological therapies 
directed at specific inflammatory mediators revolutionized the treatment but leave the 
patient more susceptible to infection by inducing a certain extent of 
immunosuppression. This includes both general infections with common agents and 
more specific complications such as tuberculosis (TB). We present a patient with IBD 
who, despite negative TB screening, developed an opportunistic miliary tuberculosis 
infection while treated with double immunosuppressive therapy (azathioprine and 
infliximab) for refractory Crohn’s disease. He presented with fever, weight loss, 
elevated transaminases, coagulopathy, anemia and neutropenia. Comprehensive 
diagnostics including computer tomography (CT) scan, bronchoscopy and liver 
biopsy revealed the diagnosis of miliary tuberculosis. Early treatment with four anti-
tubercular drugs (isoniazid, rifampicin, pyrazinamid, ethambutol) led to a rapid 
improvement of the patient’s condition. The aim of this work is to provide a literature 
review to miliary tuberculosis infection in immunosuppressed CD patients, with the 
analysis of a clinical case report.  
 
RESUMO 
A doença de Crohn é uma doença inflamatória intestinal caracterizada por uma 
resposta inflamatória inapropriada. A terapêutica com biológicos dirigidos a 
mediadores inflamatórios específicos revolucionou o tratamento mas aumentou a 
susceptibilidade a infecção ao induzir um nível de imunossupressão. Isto envolve 
infecção a agentes comuns mas também a possibilidade de tuberculose. Apresentamos 
o caso clínico de um doente com doença inflamatória intestinal que apesar do rastreio 
negativo, desenvolveu tuberculose miliar, enquanto realizava terapêutica 
imunossupressora dupla (azatioprina e infliximab) por doença de Crohn refratária. À 
admissão apresentava febre, perda ponderal, elevação das transaminases, 
coagulopatia, anemia e neutropenia. Os exames complementares de diagnóstico, que 
incluíram tomografia computorizada, broncofibroscopia e biópsia hepática, 
confirmaram o diagnóstico de tuberculose miliar. O início precoce de terapêutica anti-
tubercular quadrupla (isoniazida, rifampicina, pirazinamida, etambutol) permitiu uma 
rápida melhoria clínica do doente. O objectivo deste trabalho consiste em fornecer 
uma revisão da literatura sobre infecção por tuberculose miliar em doentes com 
doença de Crohn imunossuprimidos, com a análise de um caso clínico.  
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BACKGROUND 
Tumor necrosis factor α (TNF-α) inhibitors are established as standard treatment of 
several immune mediated inflammatory diseases such as CD. Infliximab is currently 
the most potent treatment to achieve clinical remission and mucosal healing in 
patients with CD refractory to conventional treatments, but represents an increased 
risk of opportunist infection, specially tuberculosis. 
Screening and eventually preventive chemotherapy should become the standard of 
care for individuals undergoing TNF-α antagonist, specially if it is combined with 
other immunosuppressive therapy. 
 
CASE REPORT 
A 40-year old caucasian man 
diagnosed with Crohn’s disease since 
2001, after presenting with bloody 
diarrhea and ferropenic anemia. At 
diagnosis time, disease had an 
ileocolonic location and a 
predominantly stenotic behavior, 
classified as A2L3B2 according to 
Montreal classification. Over the years 
the patient experienced disease activity 
and severity progression to dependence 
on steroids, reason for subsequent 
initiation of immunosuppression with 
azathioprine (AZA). Recently, last 
year, while on AZA maintenance 
therapy, he had developed a flare with 
an intestinal subocclusion episode, 
followed by a steroid-refractory 
course. During the in-stay, several 
immunoserologies were performed, as 
well as interferon-gamma released 
assays (IGRA), both negative. Anti-
TNF-α was proposed and after a 
thorough questioning, two negative 
tuberculin skin tests and a normal chest 
x-ray (Fig. 1), infliximab was started in 
June 2015 (induction followed by 5 
mg/kg infusion every 8 week).  
 
Fig. 1 – Normal chest x-ray performed 
before anti-TNF therapy. 
 
Early August, he presented in ER with 
flu-like symptoms as cough, 
rhinorrhea, pleuritic pain, asthenia, 
intermittent fever (max 38ºC) and non-
selective anorexia. An x-ray showed 
no alterations and azitromicin was 
prescribed for a three-day course, with 
slight improvement of the patient’s 
condition. He kept weight lost and due 
	
to a new fever episode, he was 
observed by gastroenterology late 
September. Laboratory results 
performed at the time showed anemia 
(haemoglobin: 10.8 g/dL), leukopenia 
(1600/mm3), neutropenia (1120/mm3) 
and serum level of C-reactive protein 
of 4.5 mg/dL. Febril neutropenia was 
admitted and the patient was 
hospitalized.  At admission he 
presented with fever (38ºC), polypnea, 
without other respiratory symptoms 
and a 9 Kg weight lost (82-73 Kg). 
Clinical examination showed 
hepatomegaly. He had no skin 
alterations or palpable lymph nodes. 
Chest x-ray revealed diffuse interstitial 
infiltrate (Fig. 2).  
All immunosuppressive therapies were 
immediately stopped and large 
spectrum antibiotics and support 
therapy initiated, unsuccessfully. One 
day after admission, there was no 
clinical improvement and he had  
 
 
Fig. 2 – Chest x-ray showing diffuse 
interstitial infiltrate 
 
worsening liver function tests and 
coagulopathy suggesting progressive 
hepatic cytolysis. CT imaging showed 
a bilateral and diffuse miliary pattern 
affecting the two lungs (Fig. 3a-b), 
except the lower segments of the lower 
lobes, compatible with miliary 
tuberculosis. There were also two 
irregular nodular condensations on the 
left lower lobe and left upper lobe, and 
mediastinal and para-tracheal enlarged 
lymph nodes. 
 
 
 
Fig. 3 – Chest CT imaging (a,b): bilateral and diffuse military pattern.
a	 b	
According to these findings, the 
suspicion of miliary tuberculosis in an 
immunosuppressed patient was high 
and, therefore, treatment was initiated 
with isoniazid 300 mg/day, rifampicin 
600 mg/day, pyrazinamide 1500 
mg/day and etambuthol 1200 mg/day.  
To etiologic investigation, a hepatic 
biopsy was performed due to 
hepatomegaly and analytic 
abnormalities suggestive of hepatic 
cytolysis. The anatomopatologic exam 
reported granulomatous hepatitis (Fig. 
4a-c) and acid-alcohol resistant 
bacillus (BAAR) search with Ziehl-
Neelsen (Z-N) was positive (Fig. 4d). 
Bronchoscopic aspiration and 
bronchoalveolar lavage fluids were 
taken for microbiological tests. All 
these test were negative for BAAR. 
Iatrogenic febril bicitopenia was 
admitted to be secondary to combined 
immunosuppression on a patient with 
miliary tuberculosis. The management 
was to continue anti-tubercular therapy 
and growth factor therapy, with GSF, 
was administered for three days with 
normalization of the absolute count of 
neutrophils.  
The patient is still under treatment, 
with eleven months of anti-tubercular 
therapy left. Although CD treatment 
was stopped, he has a better health 
condition, the disease remained on 
remission and he had indication to re-
initiate it after completing three 
months of anti-mycobacterium 
tuberculosis therapy. 
Fig. 4 – a: Photomicrograph showing tuberculous granuloma with Langhan giant 
multinucleated cell and lymphocytes palisade (H&E stain, x40); b: Photomicrograph 
showing portal space with lymphocytic infiltrate (H&E stain, x10); c: 
Photomicrograph showing intralobular granuloma (H&E stain, x60); d: Ziehl Neelsen 
stain: Koch’s bacillus 
b	
c	 d	
a	
DISCUSSION 
 
IBD is a chronic and disabling 
condition affecting millions of people 
in the world. The treatment algorithms 
and current guidelines result in a wider 
use of immunosuppressive and anti-
TNF-α therapy in these patients. 
Tuberculosis is also a prevalent 
disease, specially the latent form, 
witch is considered an opportunistic 
infection (OI) in the presence of an 
immunosuppressive status.    
The widespread use of anti TNF-α 
therapy, currently the most potent 
treatment to achieve clinical remission 
and mucosal healing in patients with 
Crohn’s disease refractory to 
conventional treatments represents an 
increased risk of reactivation or 
development of primary tuberculosis. 
However, only a few cases of life-
threatening disseminated tuberculosis 
have been reported (1, 2). 
Crohn’s disease is a lifelong and 
relapsing disease arising from an 
interaction between genetic and 
environmental factors, difficult both to 
diagnose and to treat. The precise 
etiology is unknown but its 
characterized by and inappropriate 
inflammatory response and therefore 
the causal therapy is not yet available 
(3, 4). Inductive therapy is followed by 
therapy to keep remission (5). Current 
therapeutic options are limited and 
comprise 5ASA, immunosuppressive 
and anti-TNF-α. 
 TNF-α has been identified as a crucial 
mediator of this abnormal immune 
response, and in recent years, 
biological therapies targeting TNF-α, 
like infliximab, have significantly 
improved the management of CD (4).  
TNF-α is a proinflammatory cytokine 
produced by activated macrophages in 
response to antigens such as M. 
tuberculosis, stimulating the 
differentiation of monocytes into 
macrophages, neutrophil recruitment 
and creation of granulomas. It is 
involved in both protection against 
Mycobacter and tuberculosis 
pathogenesis, being required for an 
effective immune response, for 
granuloma formation and to inhibit 
bacterial dissemination (2, 6). Although 
inhibiting TNF-α reduces the 
inflammatory response in the setting of 
the inappropriate inflammatory 
response seen in CD, it may in turn 
reduce the effectiveness of the host 
immune system to mount a proper 
defense against infectious organisms. 
Patients with IBD should not be 
routinely considered to have altered 
immunocompetence per se, despite 
evidence of impaired innate mucosal 
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immunity. 
Infliximab is a human murine chimeric 
monoclonal antibody with high 
binding affinity and specificity for 
TNF-α. It forms stable complexes with 
soluble and transmembrane forms of 
TNF-α and results in monocyte and 
macrophage lysis by cytotoxicity that 
depends on antibodies and complement 
(2). 
Soon after infliximab was introduced, 
large surveillance databases noted a 
significant increase in the incidence of 
TB. By 2001, 70 cases of disseminated 
TB had been reported in patients 
exposed to infliximab, with the time of 
diagnosis occurring at a median of 12 
weeks after the initial exposure to 
infliximab, and after a median of 3 
doses (6). This finding supports the 
contention that the use of this TNF-α 
inhibitor is strongly associated with the 
reactivation of latent tuberculosis into 
secondary tuberculosis. The 
infliximab-associated cases had 
unusual characteristics that may have 
caused the TB infection to be 
especially severe.  
Given the significant morbidity and 
mortality associated with TB 
reactivation, it is widely recommended 
the screening for evidence of latent 
TB. An incomplete screening could 
expose the patient to a severe, life 
threatening and disseminated form of 
tuberculosis as described in this paper. 
A full clinical history and physical 
examination should be part of the 
initial assessment and all patients 
should have a chest radiography with 
either tuberculosis skin test (TST) or 
IGRA as investigations for latent 
infection. The widespread adoption of 
this mode of screening led to 
significant reductions in the incidence 
of TB reactivation in the setting of 
TNF-α inhibitor therapy. TST has 
some disadvantages: its specificity is 
low (there are false positive in 
vaccinated subjects or due to a booster 
effect), and its sensitivity is lower in 
immunosuppressed patients than in 
healthy subjects (some 
immunosuppressed patients may have 
false negative TST). Therefore patients 
with a negative tuberculin skin test but 
who have risk factors for previous TB 
exposure should be considered for a 
secondary highly specific TB test, such 
as IGRA that detects a rise in the 
serum IFN- γ level following 
tuberculin exposure. IGRA can also be 
used for discrimination between 
anergy and true negative-antigen 
specific immune responses.  
Preventive chemotherapy against 
tuberculosis should be offered to all 
individuals before beginning anti TNF-
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α therapy whatever the underlying 
disease they are suffering from, in the 
presence of evidence of latent infection 
with M. tuberculosis. Preventive 
chemotherapy recommended is either 3 
months of isoniazid plus rifampicin or 
isoniazid alone for 9 months. If 
isoniazid cannot be used, a preventive 
chemotherapy associating rifampicin 
and pyrazinamide for 2 months could 
be delivered. Anti TNF-α therapy can 
be started after an induction period of 
3 weeks of preventive chemotherapy(2).  
The treatment of disseminated forms 
of tuberculosis has some special 
features. It consists of four drugs 
(isoniazid, rifampicin, pyrazinamide 
and ethambutol) for 2 months followed 
by 2 drugs (isoniazid, rifampicin) for 
at least 10 months. Clinician should be 
attentive to the complications of these 
prolonged treatments. 
 
CONCLUSION 
 
Opportunistic infections are a major 
cause of death in Crohn’s disease 
irrespective of comorbidity. The risk of 
infection appears to be related to 
immunosuppression and not due to 
disease itself (7). The development of 
biologics is revolutionizing the 
treatment of immune-mediated 
inflammatory diseases such as CD. On 
the other hand, this interception of 
inflammatory cytokines such as TNF-
α, which are direct factors in the 
creation of inflammation, may restrain 
protective physiological reactions and 
cause reactions that can revive 
infectious diseases such as TB that are 
in dormancy (8). An intensive 
surveillance and awareness of OI in 
CD patients requiring 
immunosuppressants should be 
performed, particularly for 
tuberculosis. 
This case highlights the severity of 
tuberculosis acquired under TNF-α 
antagonist therapies and the 
importance of a complete screening for 
latent tuberculosis.  
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